| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11845867 | PROVEPHARM SAS | Process for the preparation of indigotindisulfonate sodium (indigo carmine) |
Nov, 2036
(12 years from now) | |
| US10927258 | PROVEPHARM SAS | Process for the preparation of Indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(13 years from now) | |
| US11499050 | PROVEPHARM SAS | Process for the preparation of indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(13 years from now) | |
Bludigo is owned by Provepharm Sas.
Bludigo contains Indigotindisulfonate Sodium.
Bludigo has a total of 3 drug patents out of which 0 drug patents have expired.
Bludigo was authorised for market use on 08 July, 2022.
Bludigo is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Bludigo from 08 July, 2026.
The generics of Bludigo are possible to be released after 23 December, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 08, 2027 |
Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient
NCE-1 date: 08 July, 2026
Market Authorisation Date: 08 July, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
BLUDIGO family patents
